Informasi Investor
PT SOHO GLOBAL HEALTH TBK
| Stock Code | SOHO (Listed on the Indonesia Stock Exchange) |
|
|---|---|---|
| Company ID Number |
|
|
| Business Type | Holding Company Activities & Other Management Consulting Activities |
|
| Website | www.sohoglobalhealth.com |
|
| Establishment Year | 1956 |
|
| Stock Listing Date | 8 September 2020 |
|
| Address | Jl. Rawa Sumur II Kav. BB No. 3, Kawasan Industri Pulogadung, Kelurahan Jatinegara, Kecamatan Cakung, Jakarta Timur, 13930 |
|
| Authorized Capital | Rp 1.431.756.078.000,- |
|
| Paid Up Capital | nominal Rp 634.584.119.500,- consisting of 1.269.168.239 shares |
|
| Nominal Value | Rp 500,- |
|
| Fiscal Year | January 1st - December 31st |
|
| Contact | Corporate Secretary Tel : 62-21-2985-88888 Fax : 62-21-2985-8800 E-mail : corporate.secretary@sohoglobalhealth.com |
Struktur SOHO Group
PT SOHO Global Health, Tbk.
PT SOHO Global Investment
PT SOHO Industri Pharmasi
Natural products in prescription marketOwnership:
99,64%
SOHO Global Health
0,36%
SOHO Global Investment
PT Universal Health Network
Multilevel marketing/direct selling segmentOwnership:
99,975%
SOHO Global Health
0,025%
SOHO Global Investment
PT Parit Padang Global
The distribution arm of our businessOwnership:
99,9999%
SOHO Global Health
0,0001%
SOHO Global Investment
PT SOHO Global Medika
Medical device & medical equipment segmentOwnership:
99,8%
SOHO Global Health
0,2%
SOHO Global Investment
Dewan Komisaris
Eng Liang Tan
President Commisioner, SGH since 1997
Since taking over as President Commissioner in 1997, Eng Liang has grown SOHO Global Health’s turnover more than 20-fold. Eng Liang won the Entrepreneur of the Year Award (EOY) Award 2018 in the Lifetime Achievement Award category and EOY 2010 in the Health Product Innovation category organized by Ernst & Young.
Received Postgraduate Master Degree in Management from the University of Bradford, England and German degree as Diplom Physiker (equivalent to MSc) in Physics (specializing in Nuclear Physics) from the University of Bochum, Germany.
Harry Salam
Independent Commisioner
Past Experience includes working as Management Director of Johnson & Johnson for Singapore, Indonesia, Malaysia, and Philippines, Commercial Director at AstraZeneca Indonesia, and other companies such as Astra Pharmaceutical Co, PT. Kalbe Farma, PT. Philips Ralin Electronics, and PT. Sandoz Biochemie Farma Indonesia.
Economics Degree from University of Trisakti.
Andy Nugroho Purwohardono
Commissioner
Past Experience includes working as Director of PT. Softex Indonesia, Director of PT. MAP Active Adiperkasa Tbk, Director of PT. Matahari Department Store Tbk, President Director and Head of Investment Banking of PT. Morgan Stanley Asia Indonesia, and various positions in Intel Corp, PT. SG Securities, ABN Amro Bank, and PT. Danareksa Securities. He is also currently a Commissioner at PT. Siloam International Hospitals Tbk, Commissioner at PT. MAP Active Adiperkasa Tbk, Director at PT. Link Net Tbk, and Senior Managing Director at CVC Asia Pacific Limited.
Bachelor of Science from Oregon State University, Corvallis, Oregon, USA and Master of Business Administration from The University of Texas, San Antonio, Texas, USA.
Direksi
Rogelio Paulino Jr. Castillo La O
President Director
Past experience includes working as Regional Director of SE Asia at Smile Train, Regional Director for ASEAN and Greater China at Pfizer Consumer Healthcare, Regional Director at Pfizer Pharmaceuticals.
Master in Business Management from AIM Manila and BSc in Commerce.
Piero Brambati
Director
Past experience includes healthcare coverage for $2B long-short hedge fund, management consulting at The Boston Consulting Group, project management at GSK and Nestle.
MBA from London Business School and MSc in Mechanical Engineering.
Yuliana Tjhai
Director
Past experience includes working as a Partner at Bahar & Partners, a leading law firm based in Jakarta.
Law degree from University of Indonesia and Master Degree in International Commercial Law from University of Nottingham.
Henryk Klakurka
Director
Past experience includes working as Advisor to Mylan Vice-Chairman and CEO in Mylan Labs Inc, Chief Executive Officer of the Merck Generics Group, Regional Director of The Americas Merck Generics Group, President of Novex Pharma Inc. Apotex Inc Division, Director of Manufacturing & Logistics for Latin America, Vice President of Operations, and Vice President of the Canadian Pharmaceutical Distribution Network (CPDN), and also Vice President - Marketing then Vice President of Manufacturing at Plow Canada Inc.
Bachelor of Science degree at the University of Toronto, Astra AB Management Development Program at the IMD School Business, Lausanne Switzerland, and the Management Development Program at the University of Merck, Kellogg, Insead, Hong Kong University of Science and Technology.
Tan Ting Luen
Director
He has over 13 years of experience as an investment professional in South East Asia. Through his career, he has deployed over US$2bn of capital across multiple sectors in Healthcare, TMT, FMCG, and Consumer Retail. He is also actively involved in managing all aspect of portfolio related work including financial reporting, performance monitoring and financing. He is currently a Managing Director at CVC Asia Pacific Pte. Ltd., part of the Southeast Asia team based in Singapore. Prior to joining CVC, he was an investment professional at Navis Capital Partners in Malaysia and worked at Maxis Communication Berhad (top 3 telecommunication company listed in the Kuala Lumpur Stock Exchange) in Corporate Finance.
He holds a master’s degree in mechanical engineering with first class honors from Imperial College, London. He has also passed level II of the CFA Program.
Wonbae Lee
Director
Past Experience includes working in GE Healthcare (Tokyo, Japan) as GM of Asia-Pacific Life Sciences and GM Japan, in AstraZeneca as President, Head of Primary Care BU, and Strategic Planning Director, in McKinsey & Company as Consultant, and also in Hudson Advisors LLC and Hyundai International Merchant Bank. He is also currently a Principal at CVC Capital Partners, Singapore.
He holds a Business Administration from Korea University and Master of Business Administration from Harvard Business School.
Tim Eksekutif
-
Rogelio Paulino Jr. Castillo La O
Chief Executive Officer
-
Piero Brambati
Chief Financial Officer
-
Yuliana Tjhai
Senior Executive Vice President Legal, Compliance, Internal Audit, Corporate Secretary & Human Resources
-
Kalista Utama
Vice President Manufacturing
-
DR. Raphael Aswin
Vice President Research & Development, Regulatory, and Medical Affairs
-
Catharina Siswanti Librawati
Vice President Alliance
-
Edwin Vega Darma
Vice President Distribution Sales & Marketing
-
Pandy Harianto
Vice President Distribution Operation & Supply Chain Management
-
Sylvia Andriani Rizal
Vice President Consumer Healthcare
-
Sugiharjo
Vice President Medical Healthcare
Annual General Meeting of Shareholders
3 Mei 2021
[TEMPLATE] Surat Kuasa Menghadiri Rapat Umum Pemegang Saham Tahunan 2021
Template Surat Kuasa
View
3 Mei 2021
[BAHAN] Rapat Umum Pemegang Saham Tahunan 2021
Laporan Keuangan, Laporan Tahunan & Laporan Komite Audit, Profil, Rekomendasi Komite Audit, LRPD
View
21 Juni 2019
Rapat Umum Pemegang Saham Tahunan 2020
Pengumuman, Undangan, Agenda, dan Tata Tertib
View
21 Juni 2019
Rapat Umum Pemegang Saham Tahunan 2019
Undangan, Agenda, Tata Tertib, dan Template Surat Kuasa
ViewExtraordinary General Meeting of Shareholders
1st Extraordinary Meeting
3 Maret 2020
Rapat Umum Pemegang Saham Luar Biasa 2020
Undangan, Agenda, Tata Tertib, dan Template Surat Kuasa
View2nd Extraordinary Meeting
19 Juni 2020
Rapat Umum Pemegang Saham Luar Biasa 2020
Pengumuman, Undangan, Agenda, Klarifikasi Agenda, dan Tata Tertib
View1st Extraordinary Meeting
26 November 2019
Rapat Umum Pemegang Saham Luar Biasa
Pengumuman, Undangan, Agenda, Tata Tertib, dan Template Surat Kuasa
ViewDividen
| Dividend | Dividend per Share | Cum Dividend | Payment Date |
|---|---|---|---|
| Interim Dividend FY 2021 | 197 | 13 August 2021 | 27 August 2021 |
| Dividend | Dividend per Share | Cum Dividend | Payment Date |
|---|---|---|---|
| Final Dividend FY 2020 | 236 | 18 May 2021 | 20 May 2021 |
Harga Saham
This stock price are intended for informational purpose only and shall not be the basis for trading purposes. All information are provided by Trading View, a third-party partner. SOHO Global Health does not provide any information for this feature.
